Stay updated on Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Sign up to get notified when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.

Latest updates to the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3.SummaryDifference0.1%

- Check15 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3. It appears to be a backend/UI update with no visible changes to study details or eligibility.SummaryDifference0.1%

- Check23 days agoNo Change Detected
- Check44 days agoChange DetectedThe change consists of Revision: v3.4.2 replacing v3.4.1, which appears to be a metadata/version update without altering study content, eligibility criteria, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1.SummaryDifference0.1%

- Check58 days agoChange DetectedAdded a glossary section; updated capitalization of labels such as 'Last Update Submitted that Met QC Criteria' and the FEAR Act notice, and updated the site revision to v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check73 days agoChange DetectedRevision label updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nab-Sirolimus in Liver-Impaired Cancer Patients Clinical Trial page.